Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoproteasome subunit LMP7, also known as β5i or PSMB8, is a catalytically active component of the immunoproteasome—a specialized form of the proteasome complex predominantly found in cells of hematopoietic origin and induced by inflammatory cytokines such as interferon-gamma (IFNγ). It facilitates degradation of ubiquitin-labeled proteins and generates peptides with hydrophobic C termini suitable for binding to MHC class I molecules, enhancing antigen presentation to cytotoxic CD8+ T cells. Inhibition or deficiency leads to altered immune responses, making it a therapeutic target for autoimmune and inflammatory diseases.
Selective inhibition of LMP7 catalytic activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Low Molecular Mass Polypeptide 7 (LMP7).